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Abstract
Thrombosis — localized clotting of the blood — can occur in the arterial or the venous circulation
and has a major medical impact. Acute arterial thrombosis is the proximal cause of most cases of
myocardial infarction (heart attack) and of about 80% of strokes, collectively the most common cause
of death in the developed world. Venous thromboembolism is the third leading cause of
cardiovascular-associated death. The pathogenic changes that occur in the blood vessel wall and in
the blood itself resulting in thrombosis are not fully understood. Understanding these processes is
crucial for developing safer and more effective antithrombotic drugs.
The pathophysiology of arterial thrombosis differs from that of venous thrombosis, as reflected
by the different ways in which they are treated. In broad terms, arterial thrombosis is treated
with drugs that target platelets, and venous thrombosis is treated with drugs that target proteins
of the coagulation cascade. The available antithrombotic drugs are effective at reducing arterial
thrombosis and venous thrombosis in patients with cardiovascular disease. However, the main
side effect of these drugs is bleeding, which limits their use. To develop a new generation of
safe and effective antithrombotic drugs with larger therapeutic windows (that is, a larger
difference between the dose that prevents thrombosis and the dose that induces bleeding), a
better understanding of the pathogenic processes that lead to thrombotic occlusion of blood
vessels is needed. In this article I describe the pathological mechanisms and the risk factors
that are known to lead to arterial thrombosis and venous thrombosis, and discuss the
development of new approaches for antithrombotic therapy.
Arterial thrombosis
The primary trigger for arterial thrombosis is the rupture of an atherosclerotic plaque (Fig. 1a),
which develops through the accumulation of lipid deposits and lipid-laden macrophages (foam
cells) in the artery wall (see page 904). The thrombi that form at ruptured plaques are rich in
platelets, which are small (about 1 μm in diameter) anucleate cells produced by megakaryocytes
in the bone marrow1. These disc-shaped cells circulate in the blood as sentinels of vascular
integrity and rapidly form a primary haemostatic plug at sites of vascular injury 2. When an
atherosclerotic plaque ruptures, platelets are rapidly recruited to the site, through the interaction
of specific platelet cell-surface receptors with collagen and von Willebrand factor3,4 (Fig. 2).
After this adhesion to the vessel wall, the receptor-mediated binding of additional platelets
(termed platelet aggregation) then results in rapid growth of the thrombus. Platelets also
become activated at this stage. A major pathway of activation involves the cleavage and,
consequently, the activation of the platelet receptor PAR1 (protease-activated receptor 1; also
known as the thrombin receptor) by the protease thrombin (also known as factor II)5, which is
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activated by the blood coagulation cascade. Activated platelets then release the contents of
granules, which further promote platelet recruitment, adhesion, aggregation and activation.
The coagulation cascade (Fig. 3) is the sequential process by which coagulation factors of the
blood interact and are activated, ultimately generating fibrin, the main protein component of
the thrombus, and this cascade operates in both arterial and venous thrombosis. The cascade
is initiated by exposure of the blood to tissue factor (also known as factor III), a protein that is
present at high concentrations in atherosclerotic plaques6,7. Circulating tissue factor is also
present at increased concentrations in patients with cardiovascular disease and might contribute
to thrombosis after plaque rupture8,9.
In the case of acute thrombotic events, drugs that reduce the growth of a thrombus can be
administered; the main target of these drugs is platelets. Antiplatelet drugs are also used
prophylactically to reduce the incidence of arterial thrombosis in patients with cardiovascular
disease10. The primary targets of antiplatelet therapy are molecules involved in platelet
activation and aggregation (Box 1). At present, there are no drugs in clinical use that block the
binding of platelets to collagen and von Willebrand factor and hence their adhesion to the blood
vessel wall. In theory, inhibition of this early step in thrombus formation is more likely to
disrupt the primary role of platelets in normal blood clotting (haemostasis) and therefore to
increase the risk of bleeding. Nevertheless, such inhibitors are in development10–12.
Box 1
Antiplatelet therapy
Antiplatelet drugs are used for both the prevention and the acute treatment of arterial
thrombosis. These drugs target the activation and the aggregation of platelets. The
advantages and disadvantages of the main types of antiplatelet drug are described below.
Cyclooxygenase inhibitors
Aspirin has been used clinically for more than 40 years and is the most commonly used
antiplatelet drug. It inhibits platelet cyclooxygenase 1, which is required for the synthesis
of thromboxane A2 (TXA2), a potent activator of platelets (Fig. 2). Aspirin not only
significantly reduces the incidence of a first myocardial infarction in men at risk of
cardiovascular disease (primary prevention) but also reduces the risk in patients who have
had a myocardial infarction (secondary prevention)46,47. Aspirin therapy, however, is not
without risk and can cause stomach ulcers and bleeding.
Recent studies of the selective cyclooxygenase-2 inhibitors rofecoxib and valdecoxib have
shown that inhibiting the ‘wrong’ cyclooxygenase can lead to a significant increase in the
incidence of myocardial infarction and stroke, resulting in the withdrawal of these drugs
from the market48. It has been proposed that these inhibitors reduce cyclooxygenase-2-
dependent synthesis of prostacyclin (also known as PGI2), an inhibitor of platelet
activation48.
ADP-receptor antagonists
Another class of antiplatelet drug targets the ADP receptor P2Y12, also reducing platelet
activation49 (Fig. 2). Clopidogrel, the most widely used drug in this class, is used to treat
patients with acute coronary syndromes (which include various conditions, such as unstable
angina, that are associated with chest pain as a result of reduced blood supply to the heart)
50,51. Clopidogrel is also administered to those undergoing percutaneous coronary
intervention (a procedure in which blood flow is restored to a coronary artery by using a
catheter to remove an occlusive atherosclerotic plaque and position a stent). A recent study
compared clopidogrel with another P2Y12 antagonist, prasugrel, for the treatment of
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thrombosis in patients with acute coronary syndromes who are undergoing percutaneous
coronary intervention23. Prasugrel significantly reduced the rate of ischaemic events (12.1%
for clopidogrel versus 9.9% for prasugrel) but increased the risk of major bleeding (1.8%
for clopidogrel versus 2.4% for prasugrel); these results suggest that prasugrel is a more
potent P2Y12 inhibitor than clopidogrel.
Protease-activated-receptor-1 inhibitors
The cleavage of protease-activated receptor 1 (PAR1) by thrombin activates platelets5 (Fig.
2). PAR1 is a new target for antiplatelet therapy. Two PAR1 antagonists, E5555 and SCH
530348, are currently in phase II clinical trials10.
αIIbβ3-Integrin inhibitors
The aggregation of platelets is a crucial step in the growth of a thrombus. Inhibitors of
αIIbβ3-integrin are designed to reduce platelet aggregation by inhibiting the binding of
activated platelets to fibrinogen and other ligands (Fig. 2). Intravenously delivered
inhibitors of αIIbβ3-integrin, such as abciximab and eptifibatide, are used for the short-term
treatment of patients with acute coronary syndromes who are undergoing percutaneous
coronary intervention52. However, the use of oral αIIbβ3-integrin inhibitors is associated
with increased mortality, possibly as a result of the longer-term use of these agents and/or
their unwanted ability to act as partial agonists of αIIbβ3-integrin.
Another important treatment for acute thrombotic events is the degradation of fibrin, which
stabilizes the structure of a thrombus13, by using activators of the fibrinolytic system: namely
‘clot busters’, such as tissue plasminogen activator and streptokinase. However, the success of
such treatment depends crucially on the timing of intervention, with earlier intervention
generally having a better outcome. For example, for acute myocardial infarction, fibrinolytic
therapy seems to be beneficial for at least 12 hours after the onset of symptoms. By contrast,
fibrinolytic therapy for stroke has proven beneficial only when used within 3 hours14 and can
have the side effect of inducing brain haemorrhage. Therefore, researchers are focusing on
strategies that protect the vasculature but have a lower incidence of brain haemorrhage than is
induced by current fibrinolytic therapy.
In the past few years, studies identifying platelet receptors and signalling mechanisms have
yielded a trove of new targets for antiplatelet therapy. For example, recent studies have shown
that several cell-surface receptor–ligand interactions occur on close contact between platelets,
such as the binding of the ligand semaphorin 4D to its receptors, CD72 and plexin B1 (ref.
15). These receptors mediate platelet–platelet interactions and thrombus retraction and hence
are attractive therapeutic targets. Another example is the receptor CD36. It is well established
that CD36 functions as a scavenger receptor at the surface of macrophages: it binds to oxidized
low-density lipoproteins, resulting in the formation of foam cells and therefore contributing to
the development of atherosclerotic plaques16. CD36 is also present at the surface of platelets.
A recent study showed that oxidized low-density lipoproteins activate platelets by binding to
CD36 and that the prothrombotic phenotype of mice deficient in apolipoprotein E, which have
high concentrations of low-density lipoprotein in the circulation, is reduced by deletion of
Cd36 (ref. 17), suggesting that this interaction could explain the increased platelet reactivity
and thrombosis associated with hyperlipidaemia. Finally, the complexities of ‘outside-in’ and
‘inside-out’ signalling in platelets (that is, signalling that originates extracellularly or
intracellularly, respectively) have begun to be unravelled. However, redundancy in signalling
pathways makes it difficult to identify therapeutic targets. An exception seems to be the
essential role of the cytoskeletal protein talin 1 (ref. 18). The binding of talin 1 to the cytoplasmic
domain of β3-integrin was shown to be required for activation of αIIbβ3-integrin (also known
as glycoprotein IIB (GPIIB)–GPIIIA)19. Moreover, changing a single amino acid in the
cytoplasmic domain of β3-integrin selectively disrupted talin-1 binding and reduced arterial
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thrombosis in an animal model19, suggesting that blockade of this interaction could be a new
antithrombotic strategy.
Late stent thrombosis
In patients with symptomatic coronary artery disease, insertion of a drug-eluting stent
(delivering either sirolimus or paclitaxel) in the occluded coronary artery has become a popular
treatment. So far, about 6 million people worldwide have received drug-eluting stents. The
drugs are designed to prevent smooth muscle cell proliferation and intimal hyperplasia, which
lead to re-occlusion of the vessel (that is, to restenosis), and randomized clinical trials have
shown that drug-eluting stents reduce the rate of restenosis compared with bare metal
stents20. Individuals receiving stents are initially treated with antiplatelet agents, such as
clopidogrel (which inhibits the cell-surface receptor P2Y12). However, recent reports have
associated the use of drug-eluting stents with thrombosis after discontinuation of the
antiplatelet therapy (a phenomenon known as late stent thrombosis)21. In a report examining
the results of 14 randomized trials, the rate of late stent thrombosis was found to be fourfold-
to-fivefold higher for drug-eluting stents than for bare metal stents, with thrombosis occurring
with a median time of 15.5–18 months after stent deployment22. These results imply that
patients with drug-eluting stents might benefit from prolonged antiplatelet therapy, although
it is uncertain how long such therapy should continue. The triggering events for stent
thrombosis are unclear but probably involve incomplete endothelialization of the stent
surface21. Interestingly, the incidence of stent thrombosis was significantly lower in patients
receiving a recently developed inhibitor of platelets, prasugrel, than in those receiving the more
well-established drug in this class, clopidogrel (an incidence of 1.1% with prasugrel and 2.4%
with clopidogrel), suggesting that prasugrel could be useful for this indication23. However, a
better long-term option for reducing the incidence of late stent thrombosis will be the design
of new types of stent able to deliver drugs that can reduce smooth muscle cell proliferation
without interfering with endothelialization.
Venous thrombosis
Deep vein thrombosis and pulmonary embolism are collectively referred to as venous
thromboembolism, which is the third leading cause of cardiovascular-associated death, after
myocardial infarction and stroke. Deep vein thrombosis occurs most often in the large veins
of the legs. Pulmonary embolism is a complication of deep vein thrombosis that can occur if
part of the thrombus breaks away, travels to the lungs and lodges in a pulmonary artery,
resulting in the disruption of blood flow. Thrombi that form in veins are rich in fibrin and
trapped red blood cells and are referred to as red clots (as opposed to the platelet-rich thrombi
that form in arteries, which are referred to as white clots). Deep vein thrombosis mainly occurs
as a result of changes in the composition of the blood that promote thrombosis, changes that
reduce or abolish blood flow, and/or changes to the vessel wall24. Both genetic and
environmental factors can increase the risk of thromboembolism25,26. In inherited venous
thrombotic disease, there can be increased activity or abundance of proteins that promote
coagulation and/or decreased abundance of proteins that inhibit coagulation. For example, a
specific point mutation (present in about 5% of Caucasians) in the gene encoding factor V
results in a variant that is resistant to inactivation by the anticoagulant protease activated protein
C and therefore leads to increased clotting27. Acquired risk factors for venous
thromboembolism include cancer, obesity and major surgery 25,26. Increased amounts of
circulating tissue factor, which sits at the apex of the coagulation cascade (Fig. 3), might also
trigger venous thrombosis28–30.
Anticoagulants are used to treat a wide variety of conditions that involve arterial or venous
thrombosis, including prevention of venous thromboembolism and long-term prevention of
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ischaemic stroke in patients with atrial fibrillation. The two main classes of anticoagulant drug
are vitamin K antagonists and heparins, which target multiple proteases in the coagulation
cascade (Fig. 3 and Box 2). As is the case for antiplatelet drugs, the main side effect of
anticoagulant therapy is bleeding. Which targets are best for anticoagulant therapy and whether
the anticoagulant drugs under development will have better therapeutic windows than the
existing drugs are topics of intense debate31,32. Recent data from the RECORD 1 clinical trial
show that the anticoagulant rivaroxaban holds promise33. Rivaroxaban is an orally available
inhibitor of activated factor X (factor Xa, a component of the coagulation cascade), and it
reduced the incidence of venous thromboembolic events in patients undergoing total hip
replacement — from 3.7% in those administered a low-molecular-weight heparin (enoxaparin)
to 1.1% (ref. 33). This translates to a 70% reduction in risk without an increase in bleeding.
Box 2
Anticoagulant therapy
Anticoagulant drugs reduce the activity of various proteases in the coagulation cascade (Fig.
3) by directly inhibiting them, by inhibiting their post-translational modification or by
increasing the activity of an anticoagulant. The advantages and disadvantages of the main
types of anticoagulant are described below.
Vitamin K antagonists
Vitamin K antagonists are used for long-term anticoagulant therapy. These inhibitors,
introduced more than 50 years ago, are the only orally active anticoagulants in clinical use
today. They function by inhibiting the enzyme vitamin K epoxide reductase, which uses
vitamin K to modify several coagulation proteins (factor VII, factor IX, factor X and
prothrombin) post-translationally. Warfarin is the most commonly prescribed vitamin K
antagonist; about 1% of the US population is currently being treated with this drug. Despite
careful monitoring, the incidence of major bleeding is about 1–3% of warfarin-treated
patients per year53. The activity of warfarin is affected by diet and by genetic make-up:
polymorphisms in the gene that encodes vitamin K epoxide reductase and in the cytochrome
P450 gene CYP2C9 account for up to 50% of the interindividual variability of warfarin
dosing54. In August 2007, the US Food and Drug Administration announced a label change
for warfarin, advising that pharmacogenetic tests for polymorphisms in these two genes
could improve the accuracy of dosing.
Heparins
The anticoagulant properties of unfractionated heparin were first described in 1916. Since
then, it has become evident that heparin binds to the protein antithrombin and markedly
increases the ability of this protein to inhibit factor Xa and thrombin (Fig. 3). Unfractionated
heparin is currently used for cardiovascular surgery and for the prevention of venous
thromboembolism. Fractionated heparin, in the form of low-molecular-weight heparins,
was introduced more than 15 years ago. These molecules also target both factor Xa and
thrombin, but their administration results in a lower incidence of bleeding than does
unfractionated heparin (1.4% for low-molecular-weight heparins versus 2.3% for
unfractionated heparin)55. Synthetic pentasaccharides, such as fondaparinux and
idraparinux, have been designed with a structure based on the antithrombin-binding
sequence of heparin56. Owing to their small size, these drugs target factor Xa but not
thrombin in an antithrombin-dependent manner (as they are too short to stabilize the
interaction between antithrombin and thrombin). A complication of administering
unfractionated heparin is the syndrome of heparin-induced thrombocytopenia, which is
associated with high rates of both arterial thrombosis and venous thrombosis. More
specifically, heparin administration can result in the generation of antibodies specific for
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heparin–platelet-factor-4 complexes; these antibodies can then activate platelets, generating
thrombin and leading to thrombosis57. The incidence of heparin-induced thrombocytopenia
is reduced when low-molecular-weight heparins are used, and thrombocytopenia is rarely
observed when synthetic pentasaccharides are used.
Direct inhibitors of factor Xa and thrombin
Direct thrombin inhibitors, such as lepirudin and desirudin, are used for anticoagulant
therapy and for the treatment of patients with heparin-induced thrombocytopenia. Several
orally administered agents are in development, including: the thrombin inhibitor dabigatran,
which is as effective as the low-molecular-weight heparin enoxaparin at reducing the risk
of venous thromboembolism after hip-replacement surgery and has a similar safety
profile58; and the factor-Xa inhibitor rivaroxaban, which has a favourable balance of
efficacy and safety for preventing venous thromboembolism after major orthopaedic
surgery33,59. Several other orally administered direct inhibitors of factor Xa are also in the
pipeline40. Further studies are required to determine whether oral inhibitors of thrombin or
factor Xa can replace the use of heparins and warfarin for both short-term and long-term
anticoagulant therapy.
When targeting factors in the coagulation cascade, it is important to consider that the sequential
activation of factors by proteolytic cleavage results in an amplification of each step. Therefore,
a drug that targets an upstream component of the cascade, such as tissue factor, might be more
potent than one that targets a downstream component, such as thrombin. However, the tissue
factor and factor VIIa complex, which initiates the coagulation cascade, is essential for
haemostasis, and inhibition of this complex can lead to considerable bleeding34. Indeed, gene-
knockout experiments in mice have shown that tissue factor, as well as factor VII, factor X and
prothrombin, are essential for haemostasis and for life35.
It is also important to consider that the coagulation cascade can be subdivided into three
pathways (Fig. 3): the extrinsic pathway (tissue factor and factor VIIa), which is the primary
activator of the cascade; the intrinsic pathway (factor XIIa, factor XIa, factor IXa and factor
VIIIa), which amplifies the cascade; and the common pathway (factor Xa, factor Va and
thrombin), which generates thrombin and fibrin. In contrast to the critical nature of the extrinsic
pathway, mice can survive without components of the intrinsic pathway35. Humans deficient
in factor VIII, factor IX or factor XI have mild haemostatic defects, whereas those deficient in
factor XII have normal haemostasis36. Intrinsic-pathway components might therefore be
usefully targeted for therapy. Factor XIIa is of particular interest in this regard. A recent study
with factor-XII-deficient mice confirmed that factor XIIa is not required for haemostasis;
however, it was shown to be important for thrombosis and thus seems an inviting target for
antithrombotic therapy37. Factor IXa, part of the intrinsic pathway, has also been proposed as
a target38. Despite the possibility that the risk of bleeding is lower after inhibition of
components of the intrinsic pathway than of the common coagulation pathway, most
pharmaceutical companies have chosen to focus on inhibition of factor Xa and thrombin39,40
(Fig. 3). This might be because inhibition of the intrinsic pathway is expected to have less
impact on ongoing thrombosis than would inhibition of the downstream proteases.
An important concern about antithrombotic drugs is how to reverse their effects in the event
of bleeding. A new approach that addresses this concern uses aptamers, which are composed
of modified oligonucleotides. The first aptamer developed as an anticoagulant was targeted to
thrombin and was shown to inhibit the activity of clot-bound thrombin and to reduce the
formation of platelet-rich arterial thrombi41. More recently, an RNA aptamer that inhibits factor
IXa has been developed42. By elegant design, an ‘antidote’ oligonucleotide was also developed,
to reverse the anticoagulant activity of the inhibitory aptamer rapidly in the event of
bleeding43. The factor-IXa aptamer–antidote pair was well tolerated in a phase Ia clinical trial
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with healthy volunteers44. In another approach using oligonucleotides, antisense therapy has
been used to block not the activity of the target but its production (in this case, targeting
prothrombin)45.
Conclusions
The ‘holy grail’ for antithrombotic therapy — a drug that will prevent coagulation without
promoting bleeding — has yet to be found. However, molecules that contribute to thrombosis
continue to be identified, and these could be new targets for the next generation of
antithrombotic therapy. More immediately, recent studies of new antiplatelet drugs (such as
prasugrel) and new anticoagulant drugs (such as rivaroxaban) suggest that more options will
soon be available for the treatment of thrombosis. Furthermore, the ability to identify patients
with an increased risk of thrombosis by measuring the concentrations of circulating factors,
such as tissue factor, might allow more effective use of prophylaxis. Another exciting new
approach is combination therapy, administering both antiplatelet drugs and anticoagulant
drugs, which might prove more effective than using a single class of drug. Finally, personalized
medicine is on the horizon and should allow customized dosing of antithrombotic drugs rather
than the current ‘one dose fits all’ strategy.
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Figure 1. Triggers of arterial and venous thrombosis
a, Artery. The primary trigger of arterial thrombosis is rupture of an atherosclerotic plaque.
This involves disruption of the endothelium and release of constituents of the plaque into the
lumen of the blood vessel. b, Vein. By contrast, in venous thrombosis, the endothelium remains
intact but can be converted from a surface with anticoagulant properties to one with
procoagulant properties. Venous thrombosis can be triggered by several factors: abnormal
blood flow (such as the absence of blood flow); altered properties of the blood itself
(thrombophilia); and alterations in the endothelium.
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Figure 2. Targets of antiplatelet drugs
Platelets have a variety of cell-surface receptors that mediate their activation (green shading),
their adhesion to the blood vessel wall (red) and their aggregation with each other (blue). The
ligands for various receptors are shown. Antiplatelet drugs and their targets are also indicated;
targets include thromboxane A2 (TXA2), protease-activated receptor 1 (PAR1), the ADP
receptor P2Y12 and αIIbβ3-integrin.
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Figure 3. Targets of anticoagulant drugs
Tissue factor is present at high concentrations in atherosclerotic plaques. When exposed to the
blood — for example, when a plaque ruptures — tissue factor binds to the plasma protein factor
VIIa (the extrinsic pathway, red), and this complex triggers activation of the coagulation
cascade through the proteolytic cleavage of both factor X and factor IX. This cascade ultimately
generates fibrin (through the common pathway, orange), which (on polymerization) stabilizes
platelet thrombi. The coagulation cascade is amplified by the tenase complex, which consists
of factor VIIIa and factor IXa (components of the intrinsic pathway, blue). Factor XIa and
factor XIIa might also help to activate the coagulation cascade under pathological conditions.
Triggers of thrombosis are shown in bold face. Anticoagulant drugs that are in current use
(black) and in development (grey) are listed, and their targets are also indicated (red blocking
arrows).
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